{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T02:10:07Z","timestamp":1746411007968,"version":"3.40.4"},"publisher-location":"London","reference-count":48,"publisher":"Springer London","isbn-type":[{"type":"print","value":"9781447165026"},{"type":"electronic","value":"9781447165033"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-1-4471-6503-3_3","type":"book-chapter","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T23:27:07Z","timestamp":1412724427000},"page":"33-50","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology of Levodopa-Induced Dyskinesia"],"prefix":"10.1007","author":[{"given":"Miguel","family":"Coelho","sequence":"first","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,8,23]]},"reference":[{"issue":"3","key":"3_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358.","journal-title":"Mov Disord"},{"issue":"10","key":"3_CR2","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/jnnp.2011.240366","volume":"82","author":"JR Evans","year":"2011","unstructured":"Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson\u2019s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011;82(10):1112\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"3_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00415-011-5988-y","volume":"258","author":"C Dotchin","year":"2011","unstructured":"Dotchin C, Jusabani A, Walker R. Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson\u2019s disease in Hai, Tanzania. J Neurol. 2011;258(9):1649\u201356.","journal-title":"J Neurol"},{"issue":"Pt 11","key":"3_CR4","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A Schrag","year":"2000","unstructured":"Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study. Brain. 2000;123(Pt 11):2297\u2013305.","journal-title":"Brain"},{"issue":"3","key":"3_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/mds.23469","volume":"26","author":"MM Wickremaratchi","year":"2011","unstructured":"Wickremaratchi MM, Knipe MD, Sastry BS, et al. The motor phenotype of Parkinson\u2019s disease in relation to age at onset. Mov Disord. 2011;26(3):457\u201363.","journal-title":"Mov Disord"},{"issue":"2","key":"3_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1001\/archneur.63.2.205","volume":"63","author":"JA Gerpen Van","year":"2006","unstructured":"Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976\u20131990. Arch Neurol. 2006;63(2):205\u20139.","journal-title":"Arch Neurol"},{"issue":"6","key":"3_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/jnnp-2011-301590","volume":"83","author":"M Auyeung","year":"2012","unstructured":"Auyeung M, Tsoi TH, Mok V, et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson\u2019s disease patients. J Neurol Neurosurg Psychiatry. 2012;83(6):607\u201311.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"3_CR8","first-page":"632","volume":"89","author":"K Kulkantrakorn","year":"2006","unstructured":"Kulkantrakorn K, Tiamkao S, Pongchaiyakul C, Pulkes T. Levodopa induced motor complications in Thai Parkinson\u2019s disease patients. J Med Assoc Thai. 2006;89(5):632\u20137.","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"3_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp.67.3.300","volume":"67","author":"MA Hely","year":"1999","unstructured":"Hely MA, Morris JG, Traficante R, Reid WG, O\u2019Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson\u2019s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67(3):300\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"3_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190\u20139.","journal-title":"Mov Disord"},{"issue":"6","key":"3_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837\u201344.","journal-title":"Mov Disord"},{"issue":"6","key":"3_CR12","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/mds.10244","volume":"17","author":"CD McColl","year":"2002","unstructured":"McColl CD, Reardon KA, Shiff M, Kempster PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson\u2019s disease. Mov Disord. 2002;17(6):1227\u201334.","journal-title":"Mov Disord"},{"issue":"4","key":"3_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/1531-8257(199907)14:4<605::AID-MDS1009>3.0.CO;2-H","volume":"14","author":"KA Reardon","year":"1999","unstructured":"Reardon KA, Shiff M, Kempster PA. Evolution of motor fluctuations in Parkinson\u2019s disease: a longitudinal study over 6 years. Mov Disord. 1999;14(4):605\u201311.","journal-title":"Mov Disord"},{"issue":"16","key":"3_CR14","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/mds.23219","volume":"25","author":"IC Lopez","year":"2010","unstructured":"Lopez IC, Ruiz PJ, Del Pozo SV, Bernardos VS. Motor complications in Parkinson\u2019s disease: ten year follow-up study. Mov Disord. 2010;25(16):2735\u20139.","journal-title":"Mov Disord"},{"issue":"1","key":"3_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNF.0b013e31823dec73","volume":"35","author":"PJ Garcia-Ruiz","year":"2012","unstructured":"Garcia-Ruiz PJ, Del Val J, Fernandez IM, Herranz A. What factors influence motor complications in Parkinson disease?: a 10-year prospective study. Clin Neuropharmacol. 2012;35(1):1\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"14","key":"3_CR16","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/mds.22703","volume":"24","author":"G Fabbrini","year":"2009","unstructured":"Fabbrini G, Defazio G, Colosimo C, Suppa A, Bloise M, Berardelli A. Onset and spread of dyskinesias and motor symptoms in Parkinson\u2019s disease. Mov Disord. 2009;24(14):2091\u20136.","journal-title":"Mov Disord"},{"issue":"2","key":"3_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.33588\/rn.4502.2006599","volume":"45","author":"C Juri-Claveria","year":"2007","unstructured":"Juri-Claveria C, Aguirre MC, Viviani GP, Chana-Cuevas P. Risk factors associated with the development of motor complications in Parkinson\u2019s disease. A study in a Chilean population. Rev Neurol. 2007;45(2):77\u201380.","journal-title":"Rev Neurol"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/00207454.2013.833511","volume":"124","author":"HZ Hashim","year":"2014","unstructured":"Hashim HZ, Norlinah MI, Nafisah WY, Tan HJ, Raymond AA, Tamil AM. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson\u2019s disease. Int J Neurosci. 2014;124:187\u201391.","journal-title":"Int J Neurosci"},{"issue":"11","key":"3_CR19","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1007\/s00415-011-6067-0","volume":"258","author":"S Hassin-Baer","year":"2011","unstructured":"Hassin-Baer S, Molchadski I, Cohen OS, et al. Gender effect on time to levodopa-induced dyskinesias. J Neurol Nov. 2011;258(11):2048\u201353.","journal-title":"J Neurol Nov"},{"issue":"9","key":"3_CR20","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00415-010-5566-8","volume":"257","author":"M Coelho","year":"2010","unstructured":"Coelho M, Marti MJ, Tolosa E, et al. Late-stage Parkinson\u2019s disease: the Barcelona and Lisbon cohort. J Neurol. 2010;257(9):1524\u201332.","journal-title":"J Neurol"},{"issue":"2","key":"3_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1351-5101.2003.00727.x","volume":"11","author":"S Papapetropoulos","year":"2004","unstructured":"Papapetropoulos S, Argyriou AA, Ellul J, Chroni E. Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson\u2019s disease. Eur J Neurol. 2004;11(2):115\u20139.","journal-title":"Eur J Neurol"},{"issue":"9","key":"3_CR22","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/mds.20993","volume":"21","author":"K Sato","year":"2006","unstructured":"Sato K, Hatano T, Yamashiro K, et al. Prognosis of Parkinson\u2019s disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21(9):1384\u201395.","journal-title":"Mov Disord"},{"issue":"3","key":"3_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.parkreldis.2004.10.002","volume":"11","author":"L Mazzella","year":"2005","unstructured":"Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson\u2019s disease on L-dopa monotherapy. Parkinsonism Relat Disord. 2005;11(3):151\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"3_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00702-007-0718-4","volume":"114","author":"T Muller","year":"2007","unstructured":"Muller T, Woitalla D, Russ H, Hock K, Haeger DA. Prevalence and treatment strategies of dyskinesia in patients with Parkinson\u2019s disease. J Neural Transm. 2007;114(8):1023\u20136.","journal-title":"J Neural Transm"},{"issue":"24","key":"3_CR25","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2498\u2013508.","journal-title":"N Engl J Med"},{"issue":"2","key":"3_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1353-8020(00)00023-7","volume":"7","author":"T Caraceni","year":"2001","unstructured":"Caraceni T, Musicco M. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson\u2019s disease. A randomized multicenter study. Parkinsonism Relat Disord. 2001;7(2):107\u201314.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"3_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mds.20724","volume":"21","author":"WH Oertel","year":"2006","unstructured":"Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson\u2019s disease patients: the PELMOPET study. Mov Disord. 2006;21(3):343\u201353.","journal-title":"Mov Disord"},{"issue":"20","key":"3_CR28","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342(20):1484\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"3_CR29","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/mds.20988","volume":"21","author":"O Rascol","year":"2006","unstructured":"Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21(11):1844\u201350.","journal-title":"Mov Disord"},{"issue":"16","key":"3_CR30","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/mds.21743","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16):2409\u201317.","journal-title":"Mov Disord"},{"issue":"7","key":"3_CR31","first-page":"1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044\u201353.","journal-title":"Arch Neurol"},{"issue":"5","key":"3_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1001\/archneurol.2009.32","volume":"66","author":"Parkinson Study Group CALM Cohort Investigators","year":"2009","unstructured":"Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563\u201370.","journal-title":"Arch Neurol"},{"issue":"11","key":"3_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","volume":"18","author":"F Bracco","year":"2004","unstructured":"Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson\u2019s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733\u201346.","journal-title":"CNS Drugs"},{"issue":"9","key":"3_CR34","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1212\/WNL.57.9.1687","volume":"57","author":"AJ Lees","year":"2001","unstructured":"Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001;57(9):1687\u201394.","journal-title":"Neurology"},{"issue":"7","key":"3_CR35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","volume":"71","author":"R Katzenschlager","year":"2008","unstructured":"Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71(7):474\u201380.","journal-title":"Neurology"},{"issue":"1","key":"3_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18\u201327.","journal-title":"Ann Neurol"},{"issue":"4","key":"3_CR37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mds.22343","volume":"24","author":"RA Hauser","year":"2009","unstructured":"Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in early Parkinson\u2019s disease. Mov Disord. 2009;24(4):541\u201350.","journal-title":"Mov Disord"},{"issue":"5","key":"3_CR38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.10191","volume":"51","author":"I Shoulson","year":"2002","unstructured":"Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson\u2019s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51(5):604\u201312.","journal-title":"Ann Neurol"},{"issue":"4","key":"3_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1468-1331.2008.02514.x","volume":"16","author":"MM Wickremaratchi","year":"2009","unstructured":"Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson\u2019s disease. Eur J Neurol. 2009;16(4):450\u20136.","journal-title":"Eur J Neurol"},{"issue":"(2(Pt 1))","key":"3_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1212\/WNL.41.2_Part_1.202","volume":"41","author":"V Kostic","year":"1991","unstructured":"Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson\u2019s disease. Neurology. 1991;41((2(Pt 1))):202\u20135.","journal-title":"Neurology"},{"issue":"3","key":"3_CR41","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/mds.20360","volume":"20","author":"N Kumar","year":"2005","unstructured":"Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson\u2019s disease onset. Mov Disord. 2005;20(3):342\u20134.","journal-title":"Mov Disord"},{"issue":"8","key":"3_CR42","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jocn.2008.10.015","volume":"16","author":"WF Kum","year":"2009","unstructured":"Kum WF, Gao J, Durairajan SS, et al. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson\u2019s disease. J Clin Neurosci. 2009;16(8):1034\u20137.","journal-title":"J Clin Neurosci"},{"issue":"9","key":"3_CR43","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/mds.23068","volume":"25","author":"S Ku","year":"2010","unstructured":"Ku S, Glass GA. Age of Parkinson\u2019s disease onset as a predictor for the development of dyskinesia. Mov Disord. 2010;25(9):1177\u201382.","journal-title":"Mov Disord"},{"issue":"2","key":"3_CR44","first-page":"118","volume":"21","author":"KE Lyons","year":"1998","unstructured":"Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21(2):118\u201321.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"3_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/archneur.62.4.601","volume":"62","author":"M Zappia","year":"2005","unstructured":"Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005;62(4):601\u20135.","journal-title":"Arch Neurol"},{"issue":"2","key":"3_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00002826-200203000-00004","volume":"25","author":"M Zappia","year":"2002","unstructured":"Zappia M, Crescibene L, Arabia G, et al. Body weight influences pharmacokinetics of levodopa in Parkinson\u2019s disease. Clin Neuropharmacol. 2002;25(2):79\u201382.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"3_CR47","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1468-1331.2009.02617.x","volume":"16","author":"CG Bachmann","year":"2009","unstructured":"Bachmann CG, Zapf A, Brunner E, Trenkwalder C. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson\u2019s disease and dyskinesias. Eur J Neurol. 2009;16(8):895\u2013901.","journal-title":"Eur J Neurol"},{"issue":"8","key":"3_CR48","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.clineuro.2006.02.002","volume":"108","author":"G Benbir","year":"2006","unstructured":"Benbir G, Ozekmekci S, Apaydin H, Delil S, Erginoz E. A hospital-based study: risk factors in development of motor complications in 555 Parkinson\u2019s patients on levodopa therapy. Clin Neurol Neurosurg. 2006;108(8):726\u201332.","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Levodopa-Induced Dyskinesia in Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4471-6503-3_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T01:43:01Z","timestamp":1746409381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4471-6503-3_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9781447165026","9781447165033"],"references-count":48,"URL":"https:\/\/doi.org\/10.1007\/978-1-4471-6503-3_3","relation":{},"subject":[],"published":{"date-parts":[[2014]]}}}